What I heard about redosing 2012 was allowed as part of the confirmatory trial protocol (allowing P1/P2 patients in?) and is totally based on what the FDA wants, and as always, the FDA is in charge of every aspect of every trial anywhere. A need for urgency from shareholders is a big zero.
IMHO I heard 3005 is dead. Speaking of lack of urgency; they are in dose expansion level 3 and there would be strong demand from everyone involved if expanding sites was warranted.
I did not hear one word about upcoming partnerships. This is a stark contrast from the last two times hell-in bumped her gums publicly.
Our only hopium is the well established rumor that wallstreet sees 6 months in advance because I doubt we see or hear any real actionable news before early summer next year.